Organic acid

Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics

Retrieved on: 
Lundi, avril 8, 2024
Molecule, Research, Innovation, Patient, DNA, Wyss Institute, Engineering, Protein, Laboratory, Organic acid, Harvard University, CRISPR, Drug development, Wyss, Biological engineering, Therapy, Genetic code, FDA, Antiandrogen, Vocabulary, Fine chemical

This is the fourth Wyss project selected by Northpond Labs for additional funding.

Key Points: 
  • This is the fourth Wyss project selected by Northpond Labs for additional funding.
  • The Laboratory has previously funded the Wyss’ eRNA (now being commercialized by EnPlusOne Biosciences ), SomaCode , and Lab-on-a-Molecule projects.
  • “The AminoX platform has the potential to transform our ability to develop differentiated protein-based therapeutics by significantly expanding the vocabulary of building blocks that can be incorporated into biologics at high throughput.
  • We are thrilled that the AminoX team’s journey to the market will be accelerated by this support,” said Angelika Fretzen, Ph.D., M.B.A., the Wyss Institute’s Technology Translation Director & Chief Operating Officer.

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Retrieved on: 
Mardi, avril 9, 2024
Eurostat, Diagnosis, Civil service commission, System, Primary, Calcium oxalate, Enzyme, DSM-IV codes, Cell, Disease, Abdominal pain, Patient, Committee, Knowledge, Kidney failure, Organic acid, Regulation, EMA, IRIS, Glycine, Protein, Human, AGXT, Urine, European, COMP, Urinary tract infection, European Commission, Kidney, Safety, Blood, Marketing, Liver, Medicine, Pharmaceutical industry

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercredi, mars 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Retrieved on: 
Lundi, mars 25, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Itolizumab, Organic acid, Harvard Medical School, Exercise, Alopecia areata, ASN, Partnership, Patient, Gastrointestinal tract, ACR, IL-9, Acquisition, G&A, MPA, Dermatology, Investment, MPH, Therapy, Eosinophilic esophagitis, Retirement, Inflammatory bowel disease, Lupus nephritis, JAK, Pharmaceutical industry

Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.

Key Points: 
  • Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period in 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $3.2 million, compared with $5.2 million for the same period in 2022.
  • Net cash used in operating activities in the fourth quarter was $5.7 million.

Novoloop Appoints Worley Consulting To Conduct Preliminary Engineering Study For A 20,000-Metric Ton Facility

Retrieved on: 
Mercredi, mars 13, 2024
Engineering, Recycling, Chemicals, Plastics, Environment, Manufacturing, Sustainability, Organic acid, FOAK, Carbon, Plastic, Economics, Petrochemical

Novoloop, a leading plastic circular economy technology company, selects Worley Consulting to conduct a Front-End Loading (FEL-2) preliminary engineering study for the company’s breakthrough LifecyclingTM process.

Key Points: 
  • Novoloop, a leading plastic circular economy technology company, selects Worley Consulting to conduct a Front-End Loading (FEL-2) preliminary engineering study for the company’s breakthrough LifecyclingTM process.
  • The purpose of the study is to assess commercial project feasibility and provide a comparison framework for site selection.
  • The study evaluates a first-of-a-kind (FOAK) facility located on the US Gulf Coast, with a waste plastic processing capacity of 20,000 metric tons per annum.
  • “The completion of the FEL-2 study by Worley Consulting will solidify the project’s feasibility, ensuring that the foundational elements are in place for a seamless transition to the next stages of engineering.” - Nedim Hasanbegovic, VP of Engineering, Novoloop.

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
Lundi, mars 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

Alginates & Derivatives Market worth $651 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Mercredi, janvier 31, 2024
Alginic acid, Sodium, Gelatin, Botany, Carrageenan, Brenntag, FMC Corporation, USD, Food, Ashland Global, Dow Chemical Company, Cosmetics, Gum arabic, MCC, Organic acid, Agent handling, Region, Food industry, Textile, Printing, Explosive, Medication, Health, Gel, Textile printing

By type, sodium alginate accounted for the largest share in 2023 in terms of value in the alginates and derivatives market.

Key Points: 
  • By type, sodium alginate accounted for the largest share in 2023 in terms of value in the alginates and derivatives market.
  • By applications, the food & beverage segment is estimated to grow at a higher rate in the alginates and derivatives market.
  • Europe's overall economic stability plays a significant role in determining the trajectory of the alginates and derivatives market.
  • Key players operating in the alginates and derivatives market include Cargill Inc. (US), KIMICA Corporation (Japan), FMC Corporation (US), E.I.

Alginates & Derivatives Market worth $651 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Mercredi, janvier 31, 2024
Alginic acid, Sodium, Gelatin, Botany, Carrageenan, Brenntag, FMC Corporation, USD, Food, Ashland Global, Dow Chemical Company, Cosmetics, Gum arabic, MCC, Organic acid, Agent handling, Region, Food industry, Textile, Printing, Explosive, Medication, Health, Gel, Textile printing

By type, sodium alginate accounted for the largest share in 2023 in terms of value in the alginates and derivatives market.

Key Points: 
  • By type, sodium alginate accounted for the largest share in 2023 in terms of value in the alginates and derivatives market.
  • By applications, the food & beverage segment is estimated to grow at a higher rate in the alginates and derivatives market.
  • Europe's overall economic stability plays a significant role in determining the trajectory of the alginates and derivatives market.
  • Key players operating in the alginates and derivatives market include Cargill Inc. (US), KIMICA Corporation (Japan), FMC Corporation (US), E.I.

IFF Partners with Environmental NGO Bellona to Restore Norwegian Seaweed Forests

Retrieved on: 
Vendredi, janvier 19, 2024
Manufacturing, Specialty, Environmental Health, Food, Beverage, Agriculture, Natural Resources, Cosmetics, Retail, Environment, Sustainability, Chemicals, Plastics, Research, Health, Seaweed, Bellona Foundation, Animal, All rights reserved, Knowledge, NGO, Partnership, Science, Biomass, Registered trademark symbol, Organic acid, Climate change, Dietary supplement, Creativity, Non-governmental organization, Carrageenan, Climate, Plant

IFF (NYSE: IFF), a global leader in food and beverage, home and personal care and health, today announced its partnership with environmental non-governmental organization (NGO) Bellona in a long-term project to restore seaweed forests in northern Norway.

Key Points: 
  • IFF (NYSE: IFF), a global leader in food and beverage, home and personal care and health, today announced its partnership with environmental non-governmental organization (NGO) Bellona in a long-term project to restore seaweed forests in northern Norway.
  • The collaboration on the Norwegian Marine Restoration (NoMaRe) project aims to restore 5,000 square kilometers of seaweed forest by managing invasive sea urchin predation.
  • Norwegian seaweed forests are the main food sources and home to over 300 species of invasive sea urchins.
  • IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
Jeudi, janvier 4, 2024
Coma, Urine, Hepatic encephalopathy, Ascites, Kidney, Oliguria, Physician, Benign prostatic hyperplasia, Blood volume, Uric acid, Organic acid, Anuria, Urinary retention, NYHA, Furosemide, Cerebral edema, Hypersensitivity, Diuresis, Thrombosis, Deafness, Glucose, Azotemia, Ototoxicity, Creatinine, Tinnitus, Traction, BUN, Hypoproteinemia, Edema, Growth, Investment, Congestion, Huber loss, Patient, Bruise, Dehydration, CO2, Heart failure, Cirrhosis, Embolism, History, Erythema, Pharmaceutical industry

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.